325 related articles for article (PubMed ID: 30268633)
61. Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer Genes in Patients Lacking Known BRCA Mutations.
Caminsky NG; Mucaki EJ; Perri AM; Lu R; Knoll JH; Rogan PK
Hum Mutat; 2016 Jul; 37(7):640-52. PubMed ID: 26898890
[TBL] [Abstract][Full Text] [Related]
62. Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.
Cummings S; Roman SS; Saam J; Bernhisel R; Brown K; Lancaster JM; Usha L
J Ovarian Res; 2021 Apr; 14(1):61. PubMed ID: 33926482
[TBL] [Abstract][Full Text] [Related]
63. Contribution of Massive Parallel Sequencing to Diagnosis of Hereditary Ovarian Cancer in the Czech Republic.
Soukupová J; Lhotová K; Zemánková P; Vočka M; Janatová M; Stolařová L; Borecká M; Kleiblová P; Macháčková E; Foretová L; Koudová M; Lhota F; Tavandzis S; Zikán M; Stránecký V; Veselá K; Panczak A; Kotlas J; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):72-78. PubMed ID: 31409082
[TBL] [Abstract][Full Text] [Related]
64. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
[TBL] [Abstract][Full Text] [Related]
65. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
Ten Broeke SW; van Bavel TC; Jansen AML; Gómez-García E; Hes FJ; van Hest LP; Letteboer TGW; Olderode-Berends MJW; Ruano D; Spruijt L; Suerink M; Tops CM; van Eijk R; Morreau H; van Wezel T; Nielsen M
Gastroenterology; 2018 Sep; 155(3):844-851. PubMed ID: 29758216
[TBL] [Abstract][Full Text] [Related]
66. Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.
Golmard L; Delnatte C; Laugé A; Moncoutier V; Lefol C; Abidallah K; Tenreiro H; Copigny F; Giraudeau M; Guy C; Barbaroux C; Amorim G; Briaux A; Guibert V; Tarabeux J; Caputo S; Collet A; Gesta P; Ingster O; Stern MH; Rouleau E; de Pauw A; Gauthier-Villars M; Buecher B; Bézieau S; Stoppa-Lyonnet D; Houdayer C
Oncogene; 2016 Mar; 35(10):1324-7. PubMed ID: 26028024
[TBL] [Abstract][Full Text] [Related]
67. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
Tonin PN
Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
[TBL] [Abstract][Full Text] [Related]
68. Screening for familial cancer risk: Focus on breast cancer.
Rousset-Jablonski C; Gompel A
Maturitas; 2017 Nov; 105():69-77. PubMed ID: 28818315
[TBL] [Abstract][Full Text] [Related]
69. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
70. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M
J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684
[TBL] [Abstract][Full Text] [Related]
71. Exome sequencing in diagnostic evaluation of colorectal cancer predisposition in young patients.
Tanskanen T; Gylfe AE; Katainen R; Taipale M; Renkonen-Sinisalo L; Mecklin JP; Järvinen H; Tuupanen S; Kilpivaara O; Vahteristo P; Aaltonen LA
Scand J Gastroenterol; 2013 Jun; 48(6):672-8. PubMed ID: 23544471
[TBL] [Abstract][Full Text] [Related]
72. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
[TBL] [Abstract][Full Text] [Related]
73. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
74. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
75. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
76. Cancer genetics and reproduction.
Hanson H; Hodgson S
Best Pract Res Clin Obstet Gynaecol; 2010 Feb; 24(1):3-18. PubMed ID: 19864186
[TBL] [Abstract][Full Text] [Related]
77. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
[TBL] [Abstract][Full Text] [Related]
78. A comprehensive custom panel evaluation for routine hereditary cancer testing: improving the yield of germline mutation detection.
Velázquez C; Lastra E; Avila Cobos F; Abella L; de la Cruz V; Hernando BA; Hernández L; Martínez N; Infante M; Durán M
J Transl Med; 2020 Jun; 18(1):232. PubMed ID: 32522261
[TBL] [Abstract][Full Text] [Related]
79. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
80. Genetic mutation risk calculation in Lynch syndrome inheritance: Evaluating the utility of the PREMM
Aissaoui S; Cartellier C; Seytier T; Giraud S; Calender A
Bull Cancer; 2017 Mar; 104(3):288-294. PubMed ID: 28038733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
